1型糖尿病のアジア人成人における低血糖治療におけるダシグルカゴンとグルカゴンの比較研究と、日本人青年における同様の症状に対するダシグルカゴンの試験

基本情報

NCT ID

NCT06588504

ステータス

完了

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

38

治験依頼者名

Novo Nordisk A/S

概要

This study will be looking to confirm the effect of dasiglucagon when compared with glucagon for treating very low sugar levels in Asian adults with T1D and the effect of dasiglucagon in Japanese adolescents with T1D. This study wants to demonstrate that dasiglucagon can raise low blood sugar levels just as well as glucagon. Participants will get dasiglucagon and glucagon. In which treatment order participants get study medicines (dasiglucagon and glucagon) is decided by chance. Dasiglucagon is a new medicine, but doctors can prescribe it in the US as it is approved there. Doctors can prescribe glucagon in multiple countries including Japan as an approved medicine. The study will last for about 17 weeks. Participant cannot be in the study if the study doctor thinks that there are risks for participants health. Women cannot take part if pregnant, breast-feeding, plan to get pregnant, during the study period, or not using adequate contraceptive methods. For man: if participant have sex, participant and his partner must use an adequate birth control method during the study.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)